This series is for clinicians, nurses, APPs to have a forum to discuss the management of complex lymphoma cases. During this we discuss appropriate management options, clinical trial availability, and recently published data that would guide our decision making. We review pathology, radiological images, and clinical course for each patient presented.
Key Words: Lymphoma, Treatment, Pathology, Leukemia
- Physicians
- Nurse Practitioners
- Physician Assistants
- Nurses
- Pharmacists
- Psychologists
- Social Workers
Participants who engage in this educational intervention will be able to:
- Manage various complex lymphoma cases and review potential treatment options
- Utilize diagnostic and pathological tools utilized to characterize a lymphoma
- Improve patient outcomes through group discussion
Division of Hematology & Oncology
The Medical College of Wisconsin
Professor Department of Medicine
Division of Hematology & Oncology
The Medical College of Wisconsin
Assistant Professor Department of Medicine
Division of Hematology & Oncology
The Medical College of Wisconsin
Associate Professor Department of Medicine
Division of Hematology & Oncology
The Medical College of Wisconsin
Professor Department of Medicine
Division of Hematology & Oncology
The Medical College of Wisconsin
Professor Department of Medicine
Division of Hematology & Oncology
The Medical College of Wisconsin
- Kaitlin Annunzio, MD
- Gulrayz Ahmed, MD
- Walter Longo, MD
Name | Company | Role |
|---|---|---|
| Nirav Shah, MD | Loxo-Lilly | Advisory Board, Consultant, Researcher |
| Miltenyi Biotec | Consultant, Researcher | |
| Genentech | Advisory Board, Researcher | |
| Incyte | Advisory Board, Consultant | |
| Gilead-Kite | Advisory Board | |
| Janssen | Advisory Board | |
| BMS-Juno | Advisory Board | |
| Seattle Genetics | Advisory Board | |
| BeONE | Advisory Board | |
| Abbvie | Advisory Board | |
| Nurix | Advisory Board | |
| Astrazeneca | Advisory Board | |
| Tundra Therapeutics | Stock options | |
| Sumana Devata, MD | Novo Nordisk | Stock options |
| Glaxo Smith Kline | Stock options | |
| Abbvie | Stock options | |
| Johnson & Johnson | Stock options | |
| Eli Lilly | Stock options | |
| Merck | Stock options | |
| Pfizer | Stock options | |
| Bayer | Stock options | |
| Mehdi Hamadani, MD | ADC Therapeutics | Speaker/Researcher |
| Takeda | Researcher | |
| Spectrum Pharmaceuticals | Researcher | |
| Astellas | Researcher | |
| Caribou | Consultant | |
| BMS | Consultant | |
| Kite | Consultant, Speaker | |
| Autolus | Consultant | |
| Forte Bioscienes | Consultant | |
| Byondis | Consultant | |
| Daiichi Sankyo | Consultant | |
| Incyte | Consultant | |
| Abbvie | Consultant | |
| AstraZeneca | Speaker | |
| Beigene | Speaker | |
| Sobi | Speaker | |
| CRISPR | DMC |
Contact
ACCME Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.00 hours of participation for continuing education for allied health professionals.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:
-10 MOC points in the American Board of Pathology (ABPath) Maintenance of Certification (MOC) program; and
-10 MOC points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program.
It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABP MOC credit.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.

Facebook
X
LinkedIn
Forward